Evidence map›Paper›PMID 30167705›Full record

ReviewJAMA2018

Diagnosis and Pharmacotherapy of Alcohol Use Disorder: A Review.

Henry R Kranzler, Michael Soyka

2 registry-linked trialsOpen access · greenAbstract readReview
In one paragraph

Review in JAMA, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 325 papers, 8 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
325citing papers in PubMed, 8 pooled it
31.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05579210 nacompletednot on this mapstarted 2022, after this paper: background citation

Developing and Implementing an Online Relapse Prevention Psychotherapy Program for Patients With Alcohol Use Disorder

TypeinterventionalSponsorDr. Nazanin AlaviRan2022 to 2024Enrolled60ConditionsAlcohol Use DisorderArmsOnline relapse prevention therapy, Face to face relapse prevention therapy
NCT06620276 narecruitingnot on this mapstarted 2025, after this paper: background citation

Acceptance and Commitment Therapy in Patients With Alcohol Use Disorder and Comorbid Treatment-Resistant Depression Who Are Undergoing Ketamine Intervention: A Feasibility Study

TypeinterventionalSponsorCentre hospitalier de l'Université de Montréal (CHUM)Ran2025 to 2028Enrolled30ConditionsDepression - Major Depressive Disorder, Alcohol Use DisorderArmsAcceptance and Commitment Therapy, Ketamine
3 · Its place in the literature

Who cites it

325 citing papers in PubMed, 8 syntheses or guidelines pooled it, 565 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Canadian guideline for the clinical management of high-risk drinking and alcohol use disorder.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2023
    Guideline
  6. Pooled it
  7. Pooled it
  8. Alcohol Consumption and Cardiovascular Health.The American journal of medicine · 2022
    Pooled it
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Trial
  19. Trial
  20. Trial

265 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 2 countries.

Henry R KranzlerDepartment of Psychiatry, University of Pennsylvania Perelman School of Medicine, Philadelphia.
Michael SoykaDepartment of Psychiatry, Ludwig-Maximilians-University, Munich, Germany.
Ludwig-Maximilians-Universität München · DEUniversity of Pennsylvania · US

Funding

Pharmacogenetic Analysis of Topiramate Treatment of AUDR01AA023192 · NIAAA · UNIVERSITY OF PENNSYLVANIA · PI KRANZLER, HENRY RICHARD · 2014 to 2018
$2.7M
2/2 Pharmacogenetic Treatment for AlcoholismR01AA021164 · NIAAA · UNIVERSITY OF PENNSYLVANIA · PI KRANZLER, HENRY RICHARD, PETTINATI, HELEN M · 2012 to 2016
$2.1M
NIAAA NIH HHS R01 AA021164NIAAA NIH HHS R01 AA023192
6 · The paper itself

Abstract

Importance: Alcohol consumption is associated with 88 000 US deaths annually. Although routine screening for heavy alcohol use can identify patients with alcohol use disorder (AUD) and has been recommended, only 1 in 6 US adults report ever having been asked by a health professional about their drinking behavior. Alcohol use disorder, a problematic pattern of alcohol use accompanied by clinically significant impairment or distress, is present in up to 14% of US adults during a 1-year period, although only about 8% of affected individuals are treated in an alcohol treatment facility. Observations: Four medications are approved by the US Food and Drug Administration to treat AUD: disulfiram, naltrexone (oral and long-acting injectable formulations), and acamprosate. However, patients with AUD most commonly receive counseling. Medications are prescribed to less than 9% of patients who are likely to benefit from them, given evidence that they exert clinically meaningful effects and their inclusion in clinical practice guidelines as first-line treatments for moderate to severe AUD. Naltrexone, which can be given once daily, reduces the likelihood of a return to any drinking by 5% and binge-drinking risk by 10%. Randomized clinical trials also show that some medications approved for other indications, including seizure disorder (eg, topiramate), are efficacious in treating AUD. Currently, there is not sufficient evidence to support the use of pharmacogenetics to personalize AUD treatments. Conclusions and Relevance: Alcohol consumption is associated with a high rate of morbidity and mortality, and heavy alcohol use is the major risk factor for AUD. Simple, valid screening methods can be used to identify patients with heavy alcohol use, who can then be evaluated for the presence of an AUD. Patients receiving a diagnosis of the disorder should be given brief counseling and prescribed a first-line medication (eg, naltrexone) or referred for a more intensive psychosocial intervention.

Indexed as

AcamprosateAlcohol DeterrentsAlcoholismCounselingDisulfiramHumansNaltrexoneTaurineAcamprosateAlcohol DeterrentsDisulfiramNaltrexoneTaurine

Identifiers

PMID30167705
PMCPMC7391072
OpenAlexW2889166105

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.